|

NeuroPathways Intervention for Brain Tumor Patients

RECRUITINGN/ASponsored by Massachusetts General Hospital
Actively Recruiting
PhaseN/A
SponsorMassachusetts General Hospital
Started2023-11-07
Est. completion2026-09-10
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site

Summary

This goal of this study is to test an information and support intervention for patients with malignant (or "high-grade") brain tumors. This study was developed to help patients cope after a brain tumor diagnosis. The main question this study aims to answer is whether this intervention (which includes access to an information guide and one-on-one coaching sessions) is feasible (i.e., possible to carry out) and acceptable (i.e., considered helpful) to patients. Participants will be asked to take part in the coaching sessions, use the guide as desired, and complete a small group of short surveys at three different points in time; some participants will be asked to share feedback via exit interviews.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Age ≥18
* Massachusetts General Hospital Cancer Center patient
* Within 6 weeks of diagnosis with a primary malignant brain tumor
* Able to speak and read in English

Exclusion Criteria:

* Inability to provide informed consent as assessed by the study team (e.g., due to neurological impairment such as severe cognitive impairment/dementia or moderate-to-severe receptive aphasia)
* Deemed inappropriate to approach by patient's oncologist or study PI

Conditions4

CancerCoping SkillsGliomaMalignant Brain Tumor

Locations1 site

Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114
Deborah Forst, MA617-726-2000dforst@partners.org

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.